Oppenheimer Holdings
Joel Sendek currently serves as Managing Director and Head of Healthcare Life Sciences Research at Oppenheimer & Co. Inc. since August 2022. Prior to this role, Joel Sendek held several key positions as Chief Financial Officer at Dewpoint Therapeutics, Sema4, and Spero Therapeutics between 2017 and 2022. Other significant experience includes serving as Chief Financial Officer at Forward Pharma A/S and Managing Director at Stifel Financial Corp., Lazard, and Gerard Klauer Mattison. Joel Sendek began their career as an analyst at Goldman, Sachs & Co. and Progenics Pharmaceuticals. Joel Sendek earned a Bachelor of Arts in Biochemistry from Rice University.